First significant milestone with AsiDNA achieved
Yesterday Onxeo announced its first preclinical proof-of-concept data with AsiDNA demonstrating the potential to be administrated intravenously. AsiDNA, a first-in-class DNA repair inhibitor, has already been tested in a Phase I trial with melanoma patients and showed promising results in terms of safety and initial signs of efficacy administered via local injection. After Onxeo acquired the drug in February 2016, the company repositioned the development and now seeking to establish a pre-clinical dossier to start human trials with intravenous injection, which would vastly increase the addressable indications. Yesterday’s announcement was the first substantial step in this direction, as Onxeo showed that AsiDNA was effective alone or in combination with carboplatin in murine models of triple negative breast cancer (TNBC).Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.